Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab versus placebo in homozygous familial hypercholesterolemia
NL-OMON48741Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Started Oct 2018; status: active, not recruiting.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON48741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48741.